GlaxoSmithKline’s darapladib team finds hope in a PhIII bomb

John Carroll No matter how badly a drug fails in Phase III, investigators and the companies that employ them often bend over backward to highlight any positive sign of efficacy, no ...

Critics knock JAMA study linking testosterone drugs to cardio risks

Carly Helfand A study the FDA has cited as a reason to investigate the cardiovascular safety of testosterone drugs has come under heavy fire from critics. Physicians and researchers ...

Biogen wins FDA OK for long-acting hemophilia drug Alprolix

John Carroll FierceBiotech News

GSK buys full control of consumer unit in Indonesia

Eric Palmer Indonesia is one of the rapidly growing markets that drugmakers are trying to tap to boost sales, and GlaxoSmithKline is upping its bet. The U.K.-based drugmaker said today ...

GlaxoSmithKline pulls all U.S. alli supplies, launches product-tampering probe

Carly Helfand GlaxoSmithKline is recalling supplies of its OTC weight-loss drug alli in light of reports from U.S. consumers who found the wrong drug when they opened their bottles. FiercePharma ...

FDA panel throws dirt on Novartis’ would-be cardio blockbuster serelaxin

Damian Garde After a daylong session heavy on scathing criticism, a panel of FDA advisers voted unanimously against approving Novartis' in-development heart drug serelaxin, casting ...

Celgene wins FDA approval for its blockbuster arthritis contender

Damian Garde Celgene picked up the FDA's blessing for the much-debated apremilast, winning approval to market the oral drug as a treatment for psoriatic arthritis in step one of ...

J&J, Medivir get EU nod for their hep C drug Olysio

Eric Palmer The horse race for oral treatments of chronic hepatitis C entered another turn today as the European Union recommended approval of Olysio, the Johnson & Johnson and ...

Chelsea Therapeutics and the return of pharma’s phantom checkbook

Damian Garde Chelsea Therapeutics saw its shares soar roughly 15% on Thursday thanks to rumors that it could be in line for a Big Pharma buyout. But a deeper look at the issue reveals ...

GSK touts Anoro results as it preps for generic attacks on $8B-seller Advair

Carly Helfand With aging top dog Advair losing ground to generic and branded competitors alike, GlaxoSmithKline is grooming a lineup of respiratory up-and-comers to step in with their ...

Statins and muscle aches are unrelated

Eric Palmer So is Lipitor or Crestor causing you to have muscle aches? The answer is no, according to a new meta-analysis of the side effects of the cholesterol-lowering drugs. FiercePharma ...

Idenix takes to Europe with its Gilead patent spat

Damian Garde Idenix Pharmaceuticals believes Gilead Sciences violated its patents with the blockbuster-selling hepatitis C pill Sovaldi, and the biotech has expanded its legal fight ...
Page 1 of 212
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS